Aztreonam optional if Gram-negative pathogen was identified or suspected.4
Indeterminate outcomes occurred at rates of 5.6% (6/107) for the TEFLARO group and 11.5% (6/52) for the comparator group, and rates of clinical failure were 0% (0/107) for the TEFLARO group and 1.9% (1/52) for the comparator group.
No clinically significant differences in ceftaroline AUC were predicted in patients from
12 days to
2 months postnatal age and with ≥34 weeks of gestational age compared to adults
and pediatric patients 2 months of age and older when given the approved recommended dosage
for each patient population.
The use of TEFLARO in pediatric patients ≥34 weeks gestational age and 12 days postnatal age, and older is also supported by evidence from adequate and well-controlled studies of TEFLARO in adults along with additional pharmacokinetic and safety data from pediatric trials. See full Prescribing Information to view the clinical efficacy data in adults.
Learn about TEFLARO dosing in pediatric patients based on age and weight
SEE DOSINGPlease also see full Prescribing Information.
Please also see full Prescribing Information.